Liposomal daunorubicin

Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS related Kaposi’s sarcoma.

Trade name DaunoXome.

Administered intravenously using a liposomal carrier system that provides a favorable pharmokinetic profile at the site of malignant lesions resulting in a 10 fold increase in concentrations compared to conventional dose of daunorubicin.Robison

It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma.

Leave a Reply

Your email address will not be published. Required fields are marked *